Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 3Colorectal Neoplasms 2Pancreatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Hematologic Diseases 1Febrile Neutropenia 1Clostridium Infections 1

Interventions

Cyclophosphamide 14fludarabine 12fludarabine phosphate 8Melphalan 8Brentuximab Vedotin 8Whole-Body Irradiation 7Mycophenolic Acid 7Busulfan 7Rituximab 6Tacrolimus 5Lenalidomide 4Etoposide 4isatuximab 3Sirolimus 3Mesna 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pembrolizumab 2nilotinib 2dacetuzumab 2Vincristine 2Thiotepa 2Sugars 2Stem Cell Transplantation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Ondansetron 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Diseases × Vancomycin × Clear all
NCT03030248 2026-04-15

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Medical College of Wisconsin

Phase 2 Completed
9 enrolled 9 charts

Clostridium Infections, Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡